187 related articles for article (PubMed ID: 30964095)
1. Programmed cell death protein-1 inhibitor for the treatment of hepatocellular carcinoma: "A sharp sword".
Li X; Liang P; Ye X
J Cancer Res Ther; 2019; 15(2):267-268. PubMed ID: 30964095
[No Abstract] [Full Text] [Related]
2. Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?
Yang HY; Sun LJ; Mao YL
Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):93-94. PubMed ID: 29576280
[No Abstract] [Full Text] [Related]
3. Acute exacerbation of asthma induced by combined therapy of programmed death-1 Blocker plus lenvatinib in a patient with advanced hepatocellular carcinoma.
Wang H; Shi J; Wang X; Zhao H; Wang H
Eur J Cancer; 2021 Oct; 156():122-124. PubMed ID: 34428685
[No Abstract] [Full Text] [Related]
4. The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma.
Albin N; Monard A; Lapiere J
Cancer Chemother Pharmacol; 2019 May; 83(5):1003-1005. PubMed ID: 30830289
[No Abstract] [Full Text] [Related]
5. Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma.
Kaseb AO; Vence L; Blando J; Yadav SS; Ikoma N; Pestana RC; Vauthey JN; Allison JP; Sharma P
Cancer Immunol Res; 2019 Sep; 7(9):1390-1395. PubMed ID: 31289040
[TBL] [Abstract][Full Text] [Related]
6. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
Colombo MP
Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
[TBL] [Abstract][Full Text] [Related]
7. A novel immunosuppression-based classification of liver tumors opens new perspectives for adapted therapeutic strategies.
Bévant K; Coulouarn C
EBioMedicine; 2020 Apr; 54():102737. PubMed ID: 32268278
[No Abstract] [Full Text] [Related]
8. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
Choi B; McBride A; Scott AJ
Am J Health Syst Pharm; 2019 Oct; 76(21):1749-1752. PubMed ID: 31612928
[TBL] [Abstract][Full Text] [Related]
9. Overshadowed prospect of programmed cell death protein-1 (PD-1) inhibitor as monotherapy for patients with advanced hepatocellular carcinoma.
Yao X; Wang L; Gao J
Biosci Trends; 2019; 13(3):282-283. PubMed ID: 31327798
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation.
Zhuang L; Mou HB; Yu LF; Zhu HK; Yang Z; Liao Q; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Feb; 19(1):91-93. PubMed ID: 31706859
[No Abstract] [Full Text] [Related]
11. Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma.
Varkaris A; Lewis DW; Nugent FW
Am J Gastroenterol; 2017 Dec; 112(12):1895-1896. PubMed ID: 29215617
[No Abstract] [Full Text] [Related]
12. Nutrition and metabolism status alteration in advanced hepatocellular carcinoma patients treated with anti-PD-1 immunotherapy.
Jiang Y; Tu X; Zhang X; Liao H; Han S; Jiang W; Zheng Y; Zhao P; Tong Z; Fu Q; Qi Q; Shen J; Zhong L; Pan Y; Fang W
Support Care Cancer; 2020 Nov; 28(11):5569-5579. PubMed ID: 32361828
[TBL] [Abstract][Full Text] [Related]
13. Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future.
Armstrong SA; He AR
Clin Liver Dis; 2020 Nov; 24(4):739-753. PubMed ID: 33012456
[TBL] [Abstract][Full Text] [Related]
14. Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update.
Kudo M
Oncology; 2017; 93 Suppl 1():147-159. PubMed ID: 29258079
[TBL] [Abstract][Full Text] [Related]
15. Autologous graft-versus-host disease with combined immune checkpoint blockade.
Kofler L; Dréno B; Röcken M
Eur J Cancer; 2018 Sep; 101():275-277. PubMed ID: 30017386
[No Abstract] [Full Text] [Related]
16. Nivolumab for the treatment of hepatocellular carcinoma.
Chiew Woon L; Joycelyn Jie Xin L; Su Pin C
Expert Opin Biol Ther; 2020 Jul; 20(7):687-693. PubMed ID: 32249635
[TBL] [Abstract][Full Text] [Related]
17. BTK/PD-1 blockade for treatment of Richter's transformation.
Tang PS; Tam CS
Lancet Haematol; 2019 Feb; 6(2):e59-e60. PubMed ID: 30642820
[No Abstract] [Full Text] [Related]
18. Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity.
Martinez-Calle N; Rodriguez-Otero P; Villar S; Mejías L; Melero I; Prosper F; Marinello P; Paiva B; Idoate M; San-Miguel J
Haematologica; 2018 Jul; 103(7):e318-e321. PubMed ID: 29650641
[No Abstract] [Full Text] [Related]
19. Multiple Cranial Neuropathies From Nivolumab in a Patient With Metastatic Hepatocellular Carcinoma.
Siegel CH; Finn RS; Ho MG
Mayo Clin Proc; 2018 Apr; 93(4):540-541. PubMed ID: 29622100
[No Abstract] [Full Text] [Related]
20. A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy.
Lee SY; Kim MH; Jang M; Park Y; Cho BC
Eur J Cancer; 2018 Nov; 104():104-107. PubMed ID: 30342309
[No Abstract] [Full Text] [Related]
[Next] [New Search]
